Intuitive Surgical, Inc. $ISRG Stake Boosted by Vise Technologies Inc.

Vise Technologies Inc. boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 43.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,025 shares of the medical equipment provider’s stock after purchasing an additional 6,087 shares during the quarter. Vise Technologies Inc.’s holdings in Intuitive Surgical were worth $8,143,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ISRG. Bank of America Corp DE raised its holdings in shares of Intuitive Surgical by 3.3% during the first quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock worth $1,667,388,000 after purchasing an additional 116,292 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Intuitive Surgical in the 2nd quarter worth about $1,335,753,000. Amundi lifted its position in shares of Intuitive Surgical by 8.6% in the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after buying an additional 193,096 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Intuitive Surgical by 95.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after buying an additional 1,027,475 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Intuitive Surgical by 3.7% in the 1st quarter. Janus Henderson Group PLC now owns 1,643,060 shares of the medical equipment provider’s stock valued at $757,489,000 after buying an additional 58,587 shares during the period. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

ISRG stock opened at $436.87 on Tuesday. The stock has a market capitalization of $151.44 billion, a price-to-earnings ratio of 52.83, a PEG ratio of 3.06 and a beta of 1.46. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88. The stock’s fifty day moving average is $402.70 and its two-hundred day moving average is $433.43.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping the consensus estimate of $2.65 by $0.35. The business had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The company’s quarterly revenue was up 21.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.40 earnings per share. As a group, analysts predict that Intuitive Surgical, Inc. will post 9.37 EPS for the current fiscal year.

Analyst Ratings Changes

ISRG has been the subject of a number of recent research reports. HSBC downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 price objective for the company. in a research report on Thursday, July 30th. BNP Paribas Exane raised shares of Intuitive Surgical to an “outperform” rating in a report on Tuesday, July 28th. Stifel Nicolaus decreased their target price on Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating for the company in a research note on Friday, July 17th. Royal Bank Of Canada decreased their target price on Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating for the company in a research note on Wednesday, October 21st. Finally, Citigroup lowered their target price on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $493.54.

Insider Transactions at Intuitive Surgical

In related news, Director Craig Barratt sold 1,150 shares of Intuitive Surgical stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $443.80, for a total value of $510,370.00. Following the sale, the director directly owned 1,150 shares in the company, valued at $510,370. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 61 shares of the business’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $441.60, for a total transaction of $26,937.60. Following the transaction, the executive vice president directly owned 581 shares of the company’s stock, valued at $256,569.60. The trade was a 9.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 38,778 shares of company stock worth $16,814,967 over the last 90 days. Corporate insiders own 0.60% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.